16,970 Shares in United Therapeutics Corporation $UTHR Purchased by Nykredit A S

Key Points

• Nykredit A S purchased 16,970 United Therapeutics shares during the second quarter, valued at approximately $9.2 million. Institutional investors collectively own 94.08% of UTHR.
• United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, but revenue of $783.3 million missed forecasts and declined 1.9% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $646, while the FDA’s acceptance of Tyvaso’s application for idiopathic pulmonary fibrosis could expand the company’s addressable market.

Nykredit A S bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,970 shares of the biotechnology company's stock, valued at approximately $9,195,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Toth Financial Advisory Corp raised its stake in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock valued at $27,000 after buying an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new position in shares of United Therapeutics in the 2nd quarter worth about $30,000. WealthCollab LLC boosted its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the 4th quarter valued at about $31,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $487.61 on Friday. The stock has a market capitalization of $20.91 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.43 and a beta of 0.56. United Therapeutics Corporation has a 1-year low of $375.61 and a 1-year high of $609.35. The business's fifty day moving average price is $525.95 and its 200-day moving average price is $539.55.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. During the same quarter in the prior year, the business earned $6.41 earnings per share. United Therapeutics's revenue for the quarter was down 1.9% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: The FDA accepted United Therapeutics’ supplemental new drug application for Tyvaso in idiopathic pulmonary fibrosis (IPF). The application is supported by Phase 3 TETON data showing improved lung function and reduced clinical worsening. FDA review is expected to conclude in April 2027, and approval could materially expand Tyvaso’s addressable market. FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target near $646. However, several firms have recently lowered their targets, indicating that optimism about UTHR’s pipeline and valuation is tempered by execution and growth concerns. Analyst Sentiment on United Therapeutics
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.69 million, while EVP Paul Mahon sold 8,300 shares for about $4.00 million. Mahon’s sale reduced his holdings by 15.52%, and the transactions may be weighing on investor sentiment, even though the CEO’s sale was disclosed through an SEC filing and may have been prearranged. United Therapeutics Insider Selling
• Negative Sentiment: The latest quarterly results exceeded EPS expectations, but revenue of $783.3 million fell short of the $804.7 million consensus estimate and declined 1.9% year over year. The revenue weakness, combined with competition affecting pulmonary hypertension therapies, helps explain why investors remain cautious after earnings. United Therapeutics Earnings Performance

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on UTHR shares. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research report on Thursday, August 6th. Bank of America reduced their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Weiss Ratings downgraded United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. Finally, JPMorgan Chase & Co. lifted their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $646.00.

Insider Activity

In other news, EVP Paul Mahon sold 8,300 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $482.03, for a total value of $4,000,849.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at $21,774,259.16. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $493.46, for a total transaction of $4,687,870.00. Following the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at $160,099,642.78. This trade represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 404,075 shares of company stock valued at $214,704,893 in the last ninety days. Insiders own 8.60% of the company's stock.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source